A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
NCT ID: NCT04869592
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
3100 participants
INTERVENTIONAL
2021-04-25
2023-08-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase II clinical study will explore dose and immunization procedures in 5 age groups, including 18-59 years old group, 60-69 years old group, ≥70 years old group, 9-17 years old group, and 3-8 years old group, with a total of 3280 subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
NCT04636333
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
NCT04961359
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
NCT04550351
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
NCT05109598
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
NCT04646590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1 low-dose group
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 1 high-dose group
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 1 placebo group
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Phase 2 low-dose group A
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 low-dose group B
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 low-dose group C
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 low-dose group D
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 high-dose group A
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 high-dose group B
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 high-dose group C
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 high-dose group D
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Phase 2 placebo group A
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Phase 2 placebo group B
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Phase 2 placebo group C
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Phase 2 placebo group D
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)
Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
placebo
Intramuscular injection of placebo in the deltoid muscle of the upper arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject and/or his legal guardian and/or his entrusted person can understand the study procedures and informed consent, voluntarily sign informed consent form, and be able to comply with the requirements of the clinical study protocol;
* Inquired about medical history and physical examination, the investigator judged that the health condition is good;
* No history of SARS-CoV-2 vaccination before enrollment;
* Females of childbearing age (menarche to menopause) are not pregnant at the time of enrollment (negative urine pregnancy test), not breastfeeding, and have no birth plan within 12 months after enrollment; effective contraception will be taken within 2 weeks before enrollment;
* During the entire study follow-up period, be able and willing to complete the entire prescribed study plan.
Exclusion Criteria
* Axillary body temperature is not less than 37.3℃ (older than 14 years) before vaccination, and axillary body temperature is not less than 37.5℃ (14 years or younger) before vaccination;
* Positive in SARS-CoV-2 IgG and IgM antibody screening;
* Have a history of SARS virus infection (self-report, on-site inquiry);
* Fever (axillary temperature is not less than 37.3℃), dry cough, fatigue, nasal, congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, or dyspnea within 14 days before vaccination;
* Before vaccination, the results of blood biochemistry, blood routine, urine routine, and coagulation function related indexes are abnormal, which exceed the reference value range, and have clinical significance abnormalities (only refers to phase I);
* Previous severe allergic reaction to vaccination (such as acute allergic reaction, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain);
* Allergic to any component of the study vaccine (such as aluminum, histidine, etc.);
* Have a history of convulsions, epilepsy, encephalopathy, long-term alcoholism and drug abuse, thyroidectomy, infectious diseases, mental illness or family history;
* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
* Known or suspected diseases include: severe respiratory disease, severe liver and kidney disease, severe cardiovascular disease, drug-uncontrollable hypertension (systolic blood pressure is not less than 140mmHg, diastolic blood pressure is not less than 90mmHg), high blood glucose, diabetic complications , Malignant tumors, various acute diseases or acute attacks of chronic diseases;
* Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
* Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy);
* Asthenia or splenectomy, functional asthenia caused by any situation;
* Are receiving anti-TB (tuberculosis) treatment;
* Have received immune enhancement or inhibitor therapy within 3 months (continuous oral or instillation for more than 14 days);
* Have received a live attenuated vaccine within 28 days before vaccination, or received other vaccines within 14 days before vaccination;
* Have received blood products within 3 months before vaccination;
* Have received other study drugs within 6 months before vaccination;
* Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
* Other conditions considered by the investigator to be inappropriate for participation in the study.
* Positive urine pregnancy test;
* Have a high fever (axillary temperature is not less than 39.0℃) for three days and severe allergic reaction after the previous dose of vaccination;
* Severe adverse reactions that are causally related to the previous dose of vaccination;
* Other exclusion reasons considered by the investigator.
3 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lanzhou Institute of Biological Products Co., Ltd
INDUSTRY
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.
UNKNOWN
Zhengzhou University
OTHER
National Vaccine and Serum Institute, China
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-YM-006-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.